Screening of highly effective siRNA sequence targeting to HIV-1 vif and the lentiviral-mediated antiviral research in vitro.
- Author:
Tao ZHANG
1
;
Tong CHENG
;
Ya-Li ZHANG
;
Li-Hua WEI
;
Yi-Jun CAI
;
Jun ZHANG
;
Hua ZHU
;
Jia-Huai HAN
;
Ning-Shao XIA
Author Information
1. National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen 361005, China. zhangtnidvd@xmu.edu.cn
- Publication Type:Journal Article
- MeSH:
Acquired Immunodeficiency Syndrome;
therapy;
Base Sequence;
Humans;
Lentivirus;
genetics;
Molecular Sequence Data;
RNA Interference;
RNA, Small Interfering;
chemistry;
genetics;
Virus Replication;
vif Gene Products, Human Immunodeficiency Virus;
antagonists & inhibitors;
genetics
- From:
Chinese Journal of Virology
2008;24(2):88-95
- CountryChina
- Language:Chinese
-
Abstract:
Discovery of the RNA interference (RNAi) pathway has led to exciting new strategies for developing HIV treatment. This study was to find out the highly effective and conserved siRNA target sequences for improving RNAi-based therapy against the HIV-1. We constructed 30 shRNA expression plasmids for expressing different siRNAs targeted to HIV-1 vif and co-transfected them with the pNL4-3 to score for its ability to inhibit the expression of p24 protein of HIV-1. Then, the highly effective siRNAs targeting sequences were selected to align with 625 HIV-1 sequences in database including all HIV-1 subtypes to ana lyze their conserved character. In addition, vif37 the highly effective and most conserved target sequence was confirmed of its sequence-specific inhibition by independent reporter assays. MT-4 cell transduced with lentiviral shRNA-vif37 vector could inhibit HIV-1(NL4.3) replication in vitro. Moreover, MT-4-vif37 cloned from transduced MT-4 cell could stably express shRNA-vif37 and inhibit virus replication more efficiently when challenged with high titer virus. These results showed that RNAi has great potential as an antiviral gene therapy approach and supports the efforts to develop treatment for HIV-1-infected individuals.
